Johnson & Johnson (JNJ) on Tuesday announced positive results from the Phase 3 FUZION study evaluating TREMFYA in adults with active perianal fistulizing Crohn's disease.
The study met its primary endpoint of combined fistula remission at Week 24, defined as complete closure of all external fistula openings with no drainage, no new fistulas, and no evidence of underlying fluid collections on MRI.
The treatment showed statistically significant improvements compared with placebo, and adverse events through 24 weeks were consistent with the known safety profile of TREMFYA in Crohn's disease.
JNJ shares closed at $224.20 on Monday, down 1.32%.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.